Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Department of Statistics, University of Chicago, Chicago, IL, USA.
Phlebology. 2020 Jul;35(6):402-408. doi: 10.1177/0268355519893819. Epub 2019 Dec 10.
To examine the prescribing patterns and outcomes of antithrombotic regimens after venous stent placement.
A total of 87 patients who received inferior vena cava or iliofemoral venous stents were included in the study. A retrospective review was performed to determine the antithrombotic regimens and the subsequent rates of in-stent restenosis, stent thrombosis, and bleeding.
The prescribing patterns of specific antithrombotic regimens were highly variable. In-stent restenosis and stent thrombosis events were observed in 13 of 63 patients (21%) with available follow-up imaging, while major bleeding events were noted in 6 of 87 patients (7%). Triple therapy appeared to reduce the odds of in-stent restenosis/ stent thrombosis when compared to dual antiplatelet therapy (OR = 0.07, = 0.01).
Substantial variability exists in antithrombotic therapy following venous stenting at our institution. This study demonstrated a reduction of in-stent restenosis/thrombosis events when utilizing triple therapy compared to antiplatelet-only regimens. However, larger prospective trials are needed to more accurately determine the relative risks and benefits of each antithrombotic regimen.
研究静脉支架置入后抗栓方案的开具模式和结局。
本研究纳入了 87 例接受下腔静脉或髂股静脉支架置入的患者。回顾性分析确定抗栓方案,以及随后的支架内再狭窄、支架内血栓形成和出血发生率。
在有随访影像学资料的 63 例患者中,有 13 例(21%)出现支架内再狭窄/支架内血栓形成,87 例患者中有 6 例(7%)发生大出血事件。与双联抗血小板治疗相比,三联抗栓治疗似乎降低了支架内再狭窄/支架内血栓形成的风险(OR=0.07,P=0.01)。
本机构静脉支架置入后抗栓治疗存在很大的变异性。本研究表明,与单纯抗血小板治疗相比,三联抗栓治疗可降低支架内再狭窄/血栓形成事件的发生。然而,需要更大的前瞻性试验来更准确地确定每种抗栓方案的相对风险和获益。